Maisa Kasanga1,2,3, Lisheng Liu1,2, Linlin Xue2, Xianrang Song1. 1. University of Jinan, Clinical Laboratory of Shandong Cancer Hospital Affiliated to Shandong University, PR China. 2. School of Medicine and Life Sciences, University of Jinan, Shandong Academy of Medicine, PR China. 3. University Teaching Hospital Department of Cancer Diseases Hospital, Zambia.
Abstract
AIM: We investigated HSP90α as screening biomarker for early colorectal cancer (CRC). METHODS & RESULTS: Seventy-seven CRC patients and 78 healthy controls were enrolled. Plasma HSP90α was significantly higher in CRC patients than in healthy controls (p < 0.05). levels were higher in late (stages III and IV) CRC than in early (stages I and II) CRC (p = 0.022). HSP90α conferred an advantage in the diagnosis of early CRC. Combination of HSP90α and carcinoembryonic antigen improved the diagnostic sensitivity (84.4%) and specificity (89.5%) for CRC (area under the curve: 0.968); for early CRC, the sensitivity was 82.5% and specificity was 89.5% (area under the curve: 0.955). CONCLUSION: HSP90 is a potential biomarker for the diagnosis of early CRC.
AIM: We investigated HSP90α as screening biomarker for early colorectal cancer (CRC). METHODS & RESULTS: Seventy-seven CRC patients and 78 healthy controls were enrolled. Plasma HSP90α was significantly higher in CRC patients than in healthy controls (p < 0.05). levels were higher in late (stages III and IV) CRC than in early (stages I and II) CRC (p = 0.022). HSP90α conferred an advantage in the diagnosis of early CRC. Combination of HSP90α and carcinoembryonic antigen improved the diagnostic sensitivity (84.4%) and specificity (89.5%) for CRC (area under the curve: 0.968); for early CRC, the sensitivity was 82.5% and specificity was 89.5% (area under the curve: 0.955). CONCLUSION:HSP90 is a potential biomarker for the diagnosis of early CRC.